Navigation Links
Gen-Probe Announces Webcast of Third Quarter 2010 Earnings Conference Call
Date:10/11/2010

SAN DIEGO, Oct. 11 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will release its third quarter 2010 financial results on Thursday, October 28, 2010 at approximately 4:00 p.m. Eastern Time (ET). The announcement will be followed by a conference call with management at 4:30 p.m. ET.  

The conference call will be webcast live and may be accessed on the investors section of the Company's web site at www.gen-probe.com.  An archived version of the webcast will be available on the same web site for at least 90 days. A telephone replay also will be available for 24 hours after the call ends. To access the replay, please call 866-419-2889 (US) or 203-369-0767 (international).

About Gen-ProbeGen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.  Gen-Probe has approximately 27 years of expertise in nucleic acid testing (NAT), and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening.  Gen-Probe is headquartered in San Diego and employs approximately 1,300 people. For more information, go to www.gen-probe.com.

Caution Regarding Forward-Looking StatementsAny statements in this press release about our expectations, beliefs, plans, objectives, assumptions, future events or performance are not historical facts and are forward-looking statements.  These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would.  Forward-looking statements are not guarantees of performance.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expressed or implied.  For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and all subsequent periodic reports.  We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of subsequent events.Contact: Paula IzidoroInvestor Relations858-410-8904
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Gen-Probe Files US Regulatory Application for Molecular Test to Detect Common Sexually Transmitted Disease Trichomonas Vaginalis
2. Patrick J. Sullivan Elected to Gen-Probe Board of Directors
3. Neogen Acquires Gen-Probes BioKits Food Safety Business
4. Gen-Probe to Webcast Two Upcoming Investor Presentations
5. Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
6. Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests
7. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
8. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
9. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
10. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
11. Pioneer® Surgical Technology, Inc. Announces Plans to Establish Manufacturing and Distribution Facility in Ireland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Dehaier Medical Systems Ltd. (Nasdaq: ... develops, markets and sells medical devices and wearable ... and international markets, today announced its corporate ... the Company,s resources to develop its mobile health ... focus more on its major businesses. As of ...
(Date:2/5/2016)... France , Germany , ... Israel ). It includes a 10-year epidemiology forecast for the total ... and sex in these markets. GD epidemiology report is written and developed ... transparent and market-driven, providing expert analysis of disease trends in the 7MM. ... Italy , Spain , UK, and ...
(Date:2/4/2016)... -- Worldwide Radiology Oncology surgical robot markets are ... systems provide a way to improve traditional open ... systems pinpoint the delivery of radiation precisely, eliminating ... problem previously, limiting the quantity of radiation that ... far beyond what has been available, promising a ...
Breaking Medicine Technology:
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... the ability to correct pelvic organ prolapse with the latest techniques and the ... at greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors ...
(Date:2/7/2016)... ... 2016 , ... HealthSmart Holdings, Inc. announced today the launch ... and information to lower the costs, and increase the impact of their healthcare ... healthcare benefits by as much as 22%:, + Price and quality transparency, ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , ... with an estimated 5000 perioperative nurses in attendance to study the latest ...
(Date:2/6/2016)... , ... February 06, 2016 , ... With the ... add warm color grades to their footage. A LUT is a Lookup Table that ... to the corresponding color indicated by the table. By manipulating each pixel, LUT's can ...
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
Breaking Medicine News(10 mins):